Jeff S Piotrowski

US Patent:

20200010462, Jan 9, 2020

Filed:

Oct 24, 2017

Appl. No.:

16/344195

Inventors:

- Cambridge MA, US
Bertrand LE BOURDONNEC - Northborough MA, US
Iwona WRONA - Sharon MA, US
Bhaumik PANDYA - Bedford MA, US
Parcharee TIVITMAHAISOON - Boston MA, US
Kerem OZBOYA - Cambridge MA, US
Benjamin VINCENT - Cambridge MA, US
Daniel TARDIFF - Arlington MA, US
Jeff PIOTROWSKI - Somerville MA, US
Eric SOLIS - Milford MA, US
Robert SCANNEVIN - Hopkinton MA, US
Rebecca ARON - Cambridge MA, US
Kenneth Rhodes - Belmont MA, US

International Classification:

C07D 413/14
C07D 413/04
C07D 417/04
C07D 417/14
C07D 471/04

Abstract:

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

US Patent:

20190388397, Dec 26, 2019

Filed:

Jun 21, 2019

Appl. No.:

16/448439

Inventors:

- Cambridge MA, US
Bhaumik PANDYA - Bedford MA, US
Daniel TARDIFF - Arlington MA, US
Jeff PIOTROWSKI - Somerville MA, US
Matthew LUCAS - Lexington MA, US
Bertrand LE BOURDONNEC - Northborough MA, US
Kenneth RHODES - Belmont MA, US
Robert SCANNEVIN - Hopkinton MA, US

International Classification:

A61K 31/4196
C12N 15/113
C07K 16/40
A61K 31/496
A61K 31/506
A61K 31/4164
A61K 31/704
A61K 31/575
A61K 31/4178

Abstract:

The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression. Patients that may be treated using the compositions and methods described herein include those that express a mutant TDP-43 isoform containing a mutation associated with TDP-43-promoted aggregation and toxicity.

US Patent:

20180193325, Jul 12, 2018

Filed:

Jan 5, 2018

Appl. No.:

15/863773

Inventors:

- Cambridge MA, US
Daniel TARDIFF - Arlington MA, US
Jeff PIOTROWSKI - Somerville MA, US
Eric SOLIS - Milford MA, US
Robert SCANNEVIN - Hopkinton MA, US
Rebecca ARON - Cambridge MA, US
Bertrand LE BOURDONNEC - Northborough MA, US
Matthew LUCAS - Lexington MA, US
Kenneth RHODES - Belmont MA, US

International Classification:

A61K 31/454
A61P 25/28
G01N 33/68
A61K 45/06
A61K 31/4545
A61P 25/14
A61P 25/16

Abstract:

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

US Patent:

20150307872, Oct 29, 2015

Filed:

Apr 10, 2015

Appl. No.:

14/683724

Inventors:

- Madison WI, US
Jeff Scott Piotrowski - Madison WI, US

International Classification:

C12N 15/10
C12P 7/10

Abstract:

The present invention relates to the production of biofuels and chemical feedstocks. The present invention provides recombinant yeast having enhanced xylose fermentation capabilities. Methods of using such recombinant yeast for improved biofuel and chemical feedstock production are also provided.